Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - eplerenone - oral tablet - 50mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - eplerenone - oral tablet - 50mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - eplerenone - oral tablet - 25mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - eplerenone - oral tablet - 25mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - eplerenone - oral tablet - 25mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - eplerenone - oral tablet - 25mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - eplerenone - oral tablet - 25mg

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - eplerenone - film coated tablet - 50 milligram - aldosterone antagonists

Irlandia - Inggris - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - eplerenone - film coated tablet - 25 milligram - aldosterone antagonists

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - eplerenone, quantity: 25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium lauryl sulfate; hypromellose; magnesium stearate; macrogol 400; titanium dioxide; microcrystalline cellulose; polysorbate 80; iron oxide red; iron oxide yellow; purified talc; croscarmellose sodium - eplerenone is indicated: - to reduce the risk of cardiovascular death in combination with standard therapy in patients who have evidence of heart failure and left ventricular impairment within 3-14 days of an acute myocardial infarction (see clinical trials and dosage and administration). ; - to reduce the risk of cardiovascular mortality and morbidity in adult patients with nyha class ii (chronic) heart failure and left ventricular systolic dysfunction (lvef less than or equal to 30% or lvef less than or equal to 35% in addition to qrs duration of greater than 130 msec), in addition to standard optimal therapy (see clinical trials).